Hyperbaric Oxygen Therapy for Concussion
Trial Summary
What is the purpose of this trial?
The use of Hyberbaric Oxygen Therapy (HBOT) would be a new treatment plan rather than conventional rest. If effective, this new use technology would add to the clinical treatment among mild traumatic brain injury (mTBI) patients. The use of a point of care Glial Fibrillary Acidic Protein (GFAP) biomarker would aid in clinical decision making to create a new care plan of return to sport among unarmed combat athletes who suffer from mTBI. The innovation would be a new treatment and diagnosis strategy that will protect these athletes from serious long-term sequelae. There are no published randomized controlled studies using HBOT to treat concussed athletes within one week of injury. There are no published studies using GFAP levels to predict post concussive symptoms (PCS).
Research Team
Eligibility Criteria
This trial is for unarmed combat athletes who have recently experienced a mild traumatic brain injury (mTBI), such as a concussion, and are dealing with symptoms like headaches. They should not have had any serious injuries at home or other types of brain injuries.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Hyberbaric Oxygen Therapy (Oxygen Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Michael Harl
Lead Sponsor